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Abstract
Background: There are no prognostic factor publications on stage Ta–T1 non–muscle-
invasive bladder cancer (NMIBC) treated with 1–3 yr of maintenance bacillus Calmette-
Gue´rin (BCG).
Objective: To determine prognostic factors in NMIBC patients treatedwith 1–3 yr of BCG
after transurethral resection of the bladder (TURB), to derive nomograms and risk groups,
and to identify high-risk patients who should be considered for early cystectomy.
Design, setting, and participants: Data for 1812 patients were merged from two
European Organization for Research and Treatment of Cancer randomized phase 3 trials
in intermediate- and high-risk NMIBC.
Intervention: Patients received1–3yrofmaintenanceBCGafter TURBand inductionBCG.
Outcome measurements and statistical analysis: Prognostic factors for risk of early
recurrence and times to late recurrence, progression, and death were identiﬁed in a
training data set using multivariable models and applied to a validation data set.
Results and limitations: With a median follow-up of 7.4 yr, 762 patients recurred;
173 progressed; and 520 died, 83 due to bladder cancer (BCa). Statistically signiﬁcant
prognostic factors identiﬁed by multivariable analyses were prior recurrence rate and
number of tumors for re
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and 19.8%, respectively, and 1- and 5-yr disease-speciﬁc death rates of 4.8% and 11.3%.
Limitations include lack of repeat transurethral resection in high-risk patients and
exclusion of patients with carcinoma in situ.
Conclusions: NMIBCpatientstreatedwith1–3yrofmaintenanceBCGhaveaheterogeneous
prognosis. Patients at high risk of recurrence and/or progression do poorly on currently
recommended maintenance schedules. Alternative treatments are urgently required.
Patient summary: Non–muscle-invasive bladder cancer patients at high risk of recur-
rence and/or progression do poorly on currently recommended bacillus Calmette-
Gue´rin maintenance schedules, and alternative treatments are urgently required.
Trial registration: Study 30911 was registered with the US National Cancer Institute
clinical trials database (protocol ID: EORTC 30911). Study 30962 was registered at Clin-
icalTrials.gov, number NCT00002990; http://clinicaltrials.gov/ct2/show/record/
NCT00002990.
# 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.
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European Association of Urology (EAU) recommendations
for adjuvant treatment of non–muscle-invasive bladder
cancer (NMIBC) are based on low-, intermediate-, and high-
risk groups [1,2]. They are derived from European Organi-
zation for Research and Treatment of Cancer (EORTC) risk
tables, which provide probabilities of recurrence and
progression after transurethral resection of the bladder;
however, none of these patients received maintenance
bacillus Calmette-Gue´rin (BCG), which is now recom-
mended for high-risk patients [3].
In 1062 patients treated with a maintenance schedule of
six two-weekly BCG instillations for 5–6 mo, the Club
Urolo´gico Espan˜ol de Tratamiento Oncolo´gico (CUETO)
found that EORTC risk tables overestimated the risk of
recurrence and probability of progression in high-risk
patients [4]. CUETO stratified patients according to their
risk of recurrence and progression [5,6], which also
stratified a patient’s risk of recurrence after BCG plus
interferon-a therapy [7].
The CUETO maintenance schedule is considerably
shorter than the 1–3 yr of maintenance BCG currently
recommended by the EAU [1,2]. Prognostic factors for this
longer maintenance schedule are unknown.
Our aim was to determine prognostic factors and the
probabilities of recurrence, progression, disease-specific
survival (DSS), and overall survival (OS) in stage Ta–T1
NMIBC patients treated with 1–3 yr of maintenance BCG
and identify high-risk patients who may need early
cystectomy. We also assessed the performance of CUETO
models on EORTC data.
2. Materials and methods
Individual patient data were merged from two EORTC phase 3 trials
(30911 and 30962) in Ta–T1 NMIBC (without carcinoma in situ [CIS]).
Patients were randomized to receive 1 or 3 yr of maintenance Tice BCG
[8,9] (Supplement 1). Treatment duration had no impact on determina-
tion of the prognostic factors. Its possible impact was diluted because
40–50% of patients randomized to 3 yr ofmaintenance in the two studies
received 1 yr, mainly due to inefﬁcacy.
Patient and tumor characteristics previously investigated by EORTC
or CUETO were retrospectively analyzed: age, gender, prior recurrenceDownloaded for Anonymous User (n/a) at Centro Hospitalar Lisboa C
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1973World Health Organization (WHO) grade. The following end points
were assessed.
Time to ﬁrst recurrence (disease-free interval), deﬁned as (1) early
recurrence within the ﬁrst 4.5 mo after randomization (time between
randomization and ﬁrst follow-up cystoscopy, normally at 3 mo, which
was delayed in some patients) or (2) time to late recurrence (ﬁrst
recurrence in patients without an early recurrence who had follow-up
after 4.5 mo [Landmark analysis]). Patients still alive without recurrence
were censored at the last follow-up. The time was censored at death
and/or cystectomy in the absence of recurrence (competing risk).
Time to progression was deﬁned as the time from randomization to
ﬁrst increase to stage T2 or higher or distant metastases. Patients still
alive without progression were censored at the last follow-up. The time
was censored upon death and/or cystectomy before progression
(competing risks).
Duration of survival was deﬁned as the time from randomization to
death from any cause or last follow-up. For DSS, deaths not due to
bladder cancer (BCa) are competing risks. For both end points, patients
still alive were censored at the last follow-up.
Median follow-up in all patients was estimated using the Kaplan-
Meier technique and OS time butwith status indicator reversed: Patients
still alive were considered to have died at last follow-up, and patients
who died were censored at date of death [10].
Thedatasetwas split into twosetsbasedoncountry:a trainingset from
the largest participating countries formodel development and a validation
set (SupplementaryTable 1). Using previouspublications as a guide [3,5,6],
variables were coded based on training set univariate analyses.
Inmultivariable regressionmodels for recurrence, variables were age
(continuous), gender, prior recurrence rate (primary, less than or equal
to one recurrence per year, or more than one recurrence per year), tumor
size (<3 cm or3 cm), number of tumors (<4 or4 [6]), stage (Ta or T1),
and 1973 WHO grade (G1 or G2–G3). For progression, death due to BCa
and OS, the same variables and coding were used except for tumor size
(continuous), number of tumors (<8 or 8), and grade (G1, G2, or G3).
For early recurrence, multivariable logistic regression models were
ﬁt using Bayesian information criterion (BIC) variable selection to allow
covariates to leave the model [11].
For competing risk end points, Fine and Gray models were ﬁt using
Bayesian information criterion for competing risks (BICcr) variable
selection [12]. For OS, Cox models were ﬁt based on BIC variable
selection. Finalmodelswere based on the frequency of variables retained
using BIC/BICcr selection procedures with bootstrap resampling.
Kaplan-Meier OS curves were estimated. Based on the multivariable
model, a nomogram was constructed to predict 1- and 5-yr survival.
The nomogram provides a graphic representation linking an individual
patient’s multivariable prognostic factors to his or her survivalentral from ClinicalKey.com by Elsevier on February 01, 2018.
Copyright ©2018. Elsevier Inc. All rights reserved.
Table 1 – Patient characteristics
Training
(n = 1178)
Validation
(n = 634)
Total
(n = 1812)
n (%) n (%) n (%)
Age, yr
60 333 (28) 162 (26) 495 (27)
61–70 397 (34) 233 (37) 630 (35)
71–80 393 (33) 201 (32) 594 (33)
>80 55 (4.7) 38 (6.0) 93 (5.1)
Gender
Female 199 (17) 101 (16) 300 (17)
Male 979 (83) 530 (84) 1509 (83)
Unknown 0 (0.0) 3 (0.5) 3 (0.2)
Prior recurrence rate
Primary 635 (54) 358 (56) 993 (55)
Recurrent, 1/yr 220 (19) 121 (19) 341 (19)
Recurrent, >1/yr 297 (25) 137 (22) 434 (24)
Unknown 26 (2.2) 18 (2.8) 44 (2.4)
Largest tumor size
1 cm 517 (44) 306 (48) 823 (45)
>1 cm to <3 cm 354 (30) 196 (31) 550 (30)
3 cm 247 (21) 112 (18) 359 (20)
Unknown 60 (5.1) 20 (3.2) 80 (4.4)
No. of tumors
1 175 (15) 69 (11) 244 (13)
2–3 700 (59) 372 (59) 1072 (59)
4–7 253 (21) 138 (22) 391 (22)
8 50 (4.2) 55 (8.7) 105 (5.8)
T category
Ta 807 (69) 345 (54) 1152 (64)
T1 370 (31) 289 (46) 659 (36)
Unknown 1 (0.1) 0 (0.0) 1 (0.1)
1973 WHO grade
G1 389 (33) 191 (30) 580 (32)
G2 506 (43) 309 (49) 815 (45)
G3 280 (24) 132 (21) 412 (23)
Unknown 3 (0.3) 2 (0.3) 5 (0.3)
WHO =World Health Organization.
Table 2 – Number of events
Training
(n = 1178)
Validation
(n = 634)
Total
(n = 1812)
n (%) n (%) n (%)
Recurrence 509 253 762
Early recurrence 202 (17.1) 83 (13.1) 285 (15.7)
Late recurrence 307 170 477
Progression 116 57 173
Dead 318 202 520
Bladder cancer 59 24 83
Dead other cause 259 178 437
E U RO P E AN URO LOG Y 6 9 ( 2 0 1 6 ) 6 0 – 6 962probability. Goodness of ﬁt was assessedwith calibration plots. For other
end points, time-to-event distributions were estimated using cumula-
tive incidence curves.
Based on multivariable analyses in the training set, prognostic
factors were identiﬁed and prognostic categories formed. Categories
with similar prognoses were grouped together, with emphasis placed on
identifying the best prognosis and the worst prognosis patients. These
categories and survival regression coefﬁcients were applied to the
validation set.
Area under the curve (AUC) and Harrell’s bias-corrected concordance
index (C-index) were used to assess model accuracy (discrimination)
in the training and validation data sets [13,14]. The C-index is the
probability that for two randomly chosen patients, the patient who had
the event ﬁrst has a higher probability of having the event according to
the model. Consequently, C = 0.50 represents agreement by chance;
C = 1.0 represents perfect discrimination.
For all end points, sensitivity analyses were done stratiﬁed by study.
Sensitivity analyses also compared results of the Cox and the Fine and
Gray models.
Statistical analyses were done using SAS v.9.4 (SAS Institute, Cary,
NC, USA) and R v.3.0.1 (R Foundation, Vienna, Austria) with crrstep
package v.2014-07.16, cmprsk package v.2.2-7, and rms package v.4.2-1
for constructing nomograms.
3. Results
A total of 1812 Ta–T1 patients from EORTC studies 30962
(n = 1272 patients) and 30911 (n = 540) were included, 1180
(65%) of whom were allocated to 3 yr of maintenance BCG
and 632 (35%) to 1 yr. They were divided into training and
validationdata setswith1178and634patients, respectively.
Median age was 67 yr, 43% were recurrent, 24% had a
prior recurrence rate of more than one per year, 87% had
multiple tumors, 20% had tumors 3 cm, 36% were T1, and
23% had G3 tumors (Table 1). Patient characteristics in the
training and validation data sets were similar, except for a
higher percentage of T1 patients in the validation data set
(46% vs 31%).
After a median follow-up of 7.4 yr, 6.7 yr in patients still
alive, 762 patients recurred, 173 progressed, and 520 died,
83 due to BCa (Table 2).
The 1-and 5-yr recurrence rates were 25.9% (95%
confidence interval [CI], 23.8–27.9%) and 41.3% (95% CI,
39.0–43.7%), respectively (Supplementary Fig. 1).
Overall, 285 patients (15.7%) had an early recurrence
(Table 2). Using the training data set, the final model for
early recurrence included prior recurrence rate, number of
tumors, and grade. Table 3 shows the probabilities of early
recurrence in the training and validation data sets in the six
prognostic groups. The best prognosis patients, G1 with
fewer than four tumors and prior recurrence rate of less
than or equal to one per year, had an 8% probability of early
recurrence in the validation set. The worst prognosis group,
four ormore G2 or G3 tumors andmore than one recurrence
per year, had a 29% probability of early recurrence. For these
six groups, the AUCs were 0.67 and 0.65 in the training and
validation data sets, respectively.
Late recurrence was observed in 477 patients (Table 2).
A total of 375 patients were excluded from the analysis,
285 due to early recurrence and 90 due to no follow-up afterDownloaded for Anonymous User (n/a) at Centro Hospitalar Lisboa 
For personal use only. No other uses without permissionthe landmark. Prognostic variables in the final model were
prior recurrence rate and number of tumors. Four prognos-
tic groupswere created (Table 4). The best prognostic group,
fewer than four tumors and less than or equal to one
recurrence per year, had recurrence probabilities of 14.0%
and 28.3% at 1 yr and 5 yr, respectively, in the validation set.
The worst prognostic group, more than one recurrence per
year and four or more tumors, had recurrence probabilities
of 33.0% and 51.7% at 1 and 5 yr, respectively. The C-indexes
in the training and validation data sets were 0.59 and 0.56,
respectively. Cumulative incidence curves are provided in
Figure 1a and 1b.Central from ClinicalKey.com by Elsevier on February 01, 2018.
. Copyright ©2018. Elsevier Inc. All rights reserved.
Table 3 – Probabilities of early recurrence and 95% confidence intervals in the training and validation data sets according to prognostic
group
Six prognostic groups for early recurrence Training data set
AUC: 0.67
Validation data set
AUC: 0.65
% (95% CI) % (95% CI)
1 Grade 1
Prior recurrence 1/yr
<4 tumors
11/204
0.05 (0.03–0.09)
8/102
0.08 (0.04–0.15)
2 Grade 1
Prior recurrence >1/yr
<4 tumors
13/65
0.20 (0.12–0.31)
6/33
0.18 (0.08–0.35)
3 Grade 1
Prior recurrence 1/yr
4 tumors
Grade 2 or 3
Prior recurrence 1/yr
<4 tumors
75/540
0.14 (0.11–0.17)
26/290
0.09 (0.06–0.13)
4 Grade 1
Prior recurrence >1/yr
4 tumors
Grade 2 or 3
Prior recurrence >1/yr
<4 tumors
46/154
0.30 (0.23–0.37)
8/56
0.14 (0.07–0.26)
5 Grade 2 or 3
Prior recurrence 1/yr
4 tumors
24/109
0.22 (0.15–0.31)
21/87
0.24 (0.16–0.34)
6 Grade 2 or 3
Prior recurrence >1/yr
4 tumors
31/77
0.40 (0.30–0.51)
14/48
0.29 (0.18–0.43)
Missing 2/29 0/18
Total 202/1178 83/616
AUC = area under the curve; CI = conﬁdence interval.
E U RO P E AN URO LOG Y 6 9 ( 2 0 1 6 ) 6 0 – 6 9 63The multivariable model for disease progression identi-
fied two variables: grade and T category, with four
prognostic groups (Table 5). The best prognostic group,
TaG1 patients, had a progression probability of 1.9% at 1 yr
and 7.1% at 5 yr in the validation data set. The worst
prognostic group, T1G3 patients, had a progression
probability of 11.4% at 1 yr and 19.8% at 5 yr (Table 5;
Fig. 2a and 2b). The C-indexes in the training and validation
data sets were 0.72 and 0.64, respectively.
A total of 83 of 520 deaths were due to BCa. The same
variables as for progression were of prognostic importance,
grade and T category, and the same prognostic groups were
formed (Table 6). TaG1, the best prognostic group, had a
probability of death due to BCa of 1.5% at 5 yr in the
validation set. The worst prognostic group, T1G3, had a
probability of death due to BCa of 4.8% at 1 yr and 11.3% at
5 yr (Table 6). The C-indexes in the training and validation
data sets were 0.72 and 0.71, respectively. Cumulative
incidence curves are given in Figure 3a and 3b.Table 4 – Probabilities of late recurrence and 95% confidence intervals i
Training data set: C-index 0.59
1 yr, % (95% CI) 5 yr, %
Prior recurrence 1/yr
and <4 tumors
11.0
(8.4–13.5)
25.9
(22.1–2
Prior recurrence 1/yr
and 4 tumors
20.6
(13.9–27.3)
31.6
(23.7–3
Prior recurrence >1/yr
and <4 tumors
23.8
(16.5–31.2)
39.6
(30.9–4
Prior recurrence >1/yr
and 4 tumors
31.2
(20.1–42.3)
55.4
(43.1–6
CI = conﬁdence interval.
* The maximum achievable C-index in both groups was 0.90 [14].
Downloaded for Anonymous User (n/a) at Centro Hospitalar Lisboa C
For personal use only. No other uses without permission. The final multivariable survival model included age
and grade. The C-indexes in the training and validation
data sets were both 0.68. Model calibration was checked
with calibration plots (Supplementary Fig. 2a and 2b).
Supplementary Figure 3a, 3b, 4a, and 4b present Kaplan-
Meier curves according toageandgrade, respectively, inboth
data sets. Figure4provides anomogram for survival basedon
age and grade. Points associated with the nomogram are
given in Supplementary Table 2. For example, a patient aged
65 yr with a G3 tumor has 79 points (67 + 12), with survival
probabilities of 97% at 1 yr and 78% at 5 yr. Sensitivity
analyses offered the same conclusions for all end points.
CUETO recurrence and progression scores were calculat-
ed on EORTC data [6]. Time to recurrence and time to
progression cumulative incidence curves were estimated
(Supplementary Fig. 5a and 5b). The CUETO model did not
perform as well when applied to EORTC data. The C-indexes
for recurrence and progression decreased from 0.64 to
0.48 and from 0.69 to 0.53, respectively. Applied to EORTCn the training and validation data sets according to prognostic group
* Validation data set: C-index 0.56*
(95% CI) 1 yr, % (95% CI) 5 yr, % (95% CI)
9.6)
14.0
(10.2–17.9)
28.3
(23.1–33.6)
9.5)
16.3
(8.5–24.1)
31.0
(20.8–41.3)
8.2)
21.8
(11.3–32.3)
42.4
(29.3–55.5)
7.6)
33.0
(19.3–46.7)
51.7
(36.9–66.6)
entral from ClinicalKey.com by Elsevier on February 01, 2018.
Copyright ©2018. Elsevier Inc. All rights reserved.
[(Fig._1)TD$FIG]
Fig. 1 – Time to late recurrence according to prognostic groups: (a) training set; (b) validation set.
E U RO P E AN URO LOG Y 6 9 ( 2 0 1 6 ) 6 0 – 6 964data, the CUETO model underestimated the risk of recur-
rence in good risk patients and overestimated the risk of
progression at 5 yr in poor risk patients.
4. Discussion
This paper presents the first prognostic factor analysis
in NMIBC patients receiving the currently recommended
1–3 yr ofmaintenance BCG and identified prognostic factors
for recurrence, progression, DSS, and OS.
The analysis made a distinction between early recur-
rence that may be influenced by unintended incompleteDownloaded for Anonymous User (n/a) at Centro Hospitalar Lisboa 
For personal use only. No other uses without permissionresection [15] and late recurrence in patients who are
disease free at the first follow-up cystoscopy. The most
important prognostic factors for early recurrence were
prior recurrence rate, number of tumors, and grade. The
prior recurrence rate and number of tumors were also
the most important factors for time to recurrence in
patients without early recurrence. These results corre-
spond with those from the EORTC [3] and CUETO [5,6].
However, CUETO also identified the prognostic impor-
tance of age and gender.
For progression, the most important factors were stage
and grade, which were also previously identified by EORTCCentral from ClinicalKey.com by Elsevier on February 01, 2018.
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Table 5 – Probabilities of progression and 95% confidence intervals in the training and validation data sets according to stage and grade
Training data set: C-index 0.72 Validation data set: C-index 0.64
1 yr, % (95% CI) 5 yr, % (95% CI) 1 yr, % (95% CI) 5 yr, % (95% CI)
TaG1 0.28
(0–0.82)
2.4
(0.76–4.1)
1.9
(0–4.1)
7.1
(2.8–11.4)
TaG2 or T1G1 2.5
(0.97–4.0)
7.0
(4.4–9.6)
1.6
(0–3.4)
4.6
(1.5–7.7)
TaG3 or T1G2 3.5
(0.75–6.3)
15.2
(9.6–20.8)
1.8
(0–3.8)
5.9
(2.1–9.6)
T1G3 10.6
(6.5–14.7)
18.9
(13.6–24.4)
11.4
(5.3–17.5)
19.8
(12.0–27.6)
CI = conﬁdence interval.
[(Fig._2)TD$FIG]
Fig. 2 – Time to progression according to prognostic groups: (a) training set; (b) validation set.
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Table 6 – Probabilities of death due to bladder cancer and 95% confidence intervals in the training and validation datasets according to stage
and grade
Training data set: C-index 0.72 Validation data set: C index 0.71
1 yr, % (95% CI) 5 yr, %(95% CI) 1 yr, % (95% CI) 5 yr, % (95% CI)
TaG1 0: no events 0.87
(0–1.9)
0: no events 1.5
(0–3.6)
TaG2 or T1G1 0.75
(0–1.6)
3.6
(1.7–5.6)
0: no events 1.7
(0–3.6)
TaG3 or T1G2 0: no events 7.1
(3.1–11.2)
0: no events 1.4
(0–3.3)
T1G3 1.9
(0.05–3.7)
11.5
(6.9–16.0)
4.8
(0.70–8.9)
11.3
(5.0–17.6)
[(Fig._3)TD$FIG]
Fig. 3 – Disease-specific survival according to prognostic groups: (a) training set; (b) validation set.
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Points
0 10 20 30 40 50 60 70 80 90 100
Age
25 30 35 40 45 50 55 60 65 70 75 80 85
G category
1 3
2
Total points
0 10 20 30 40 50 60 70 80 90 100 110 120 130
1-yr survival probability
0.999 0.998 0.99 0.98 0.97 0.96 0.95 0.93 0.9
5-yr survival probability
0.99 0.98 0.97 0.96 0.95 0.93 0.9 0.85 0.8 0.75 0.7 0.65 0.6 0.5  0.45 0.3 0.25
Fig. 4 – Nomogram overall survival according to age and grade.
E U RO P E AN URO LOG Y 6 9 ( 2 0 1 6 ) 6 0 – 6 9 67and CUETO. As expected, T1G3 patients had the worst
prognosis with 1- and 5-yr progression rates of 11.4% and
19.8%, respectively.
CUETO models for recurrence and progression are
‘‘optimized’’ for their data set and do not perform as well
when applied to EORTC data. The longer duration of BCG in
EORTC studies may have also had an impact on the results.
For the first time, prognostic factor analyses for both DSS
and OS are provided. For DSS, the most important factors
were the same as for progression: stage and grade. T1G3
patients had the worst prognosis with 1- and 5-yr disease-
specific death rates of 4.8% and 11.3%, respectively.
Although grade remained statistically significant for OS,
age was the dominant factor (Fig. 4). The clinical utility of
this nomogram in daily practice still needs to be proven.
Patients previously identified at the highest risk of
recurrence [3,5,6] still remain at high risk even when
treated with 1–3 yr of maintenance BCG. Patients with four
ormore tumors and a prior recurrence rate ofmore than one
per year have a probability of recurrence at 1 and 5 yr of
33.0% and 51.7%, respectively, even if no tumor was
detected at the first follow-up cystoscopy.With recurrences
after >10 yr, our study along with studies from CUETO,
SWOG, and FinnBladder show the need for long-term
follow-up in NMIBC patients [5,6,16,17].
Many patients do well on maintenance, with a 5-yr
recurrence-free rate of 58.7%. Although we can accurately
identify patients who do not progress or die due to theirDownloaded for Anonymous User (n/a) at Centro Hospitalar Lisboa C
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progress, and 98% do not die due to their disease), we
cannot reliably identify the important subgroup of patients
who do progress and die of their disease. Patients with T1G3
tumors, even without CIS, do relatively poorly, with 5-yr
progression- and disease-specific death rates of 19.8% and
11.3%, respectively, but we need improved methods to
identify the really high-risk patients and develop effective
treatments for them.
Because the number of tumors and prior recurrence rate
have also been shown to contribute to a worse prognosis,
T1G3 patients with recurrent and/or multiple lesions
should be considered for early cystectomy instead of
BCG, especially if they have concomitant CIS, as concluded
by Gontero et al [18]. However, we need better markers of
immune response and molecular profiling to optimize
patient selection and treatment strategy [19,20].
This data set has a number of limitations. No patients
with CIS were included. Both studies were carried out when
routine repeat transurethral resectionwas not performed in
high-risk patients. This could have contributed to under-
staging that may have led to higher progression rates,
especially in T1G3 patients. There was no central pathology
review. No information was collected on the status of the
upper urinary tract upon recurrence or progression or on
potential biomarkers. It was not possible to make a
meaningful distinction between 1 yr and 3 yr of mainte-
nance in the analysis. Nevertheless, this study provides theentral from ClinicalKey.com by Elsevier on February 01, 2018.
Copyright ©2018. Elsevier Inc. All rights reserved.
E U RO P E AN URO LOG Y 6 9 ( 2 0 1 6 ) 6 0 – 6 968best available information about the prognosis of patients
treated with the currently recommended 1–3 yr of mainte-
nance BCG.
5. Conclusions
NMIBC patients treated with 1–3 yr of maintenance BCG
have a heterogeneous prognosis for both time to first
recurrence (according to the prior recurrence rate and
number of tumors) and time to progression and death due
to BCa (based on tumor stage and grade).
Patients at high risk of recurrence and/or progression
still do poorly on current maintenance schedules. Alterna-
tive treatments are urgently required.
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